ID: MRFR/Pharma/1390-HCR | February 2021 | Region: Global | 110 pages
As the name indicates, bone cancer develops in the skeletal system and degrades bone tissues. Bone cancer can be benign or malignant. Persistent bone pain, lump over bones, and weakness of bones are some of the common symptoms for the disease. If such symptoms remain unchecked, bone cancer can become life-threating. Thus, timely diagnosis and treatment of the disease is crucial. This provides the developmental backgrounds for market growth.
From the past few years, it has been observed that the prevalence of bone cancer has increased. Approximately 3,500 people were diagnosed with primary bone cancer in the US in 2018. Moreover, favorable reimbursement policies, increasing healthcare expenditure, rising R&D investments by the market key players, and growing awareness are estimated to drive the bone cancer market during the projected period. Therapeutic surgeries, including ablation therapy (against bone disease), are reimbursed under CPT code 20982. Such policies increase the number of patients who seek treatment for bone cancer.
However, the high cost of medicinal therapies and related side effects followed by poor healthcare infrastructure in developing countries is restricting the bone cancer market growth.
Bone Cancer Market is estimated to grow at a healthy CAGR of 5.6% from 2018–2025.
Bone Cancer Market Segmentation
The Bone Cancer Market has been segmented into type, diagnostic test & treatment, end user, and region.
The global market, based on type, has been divided into anterior bone cancer and posterior bone cancer. The anterior bone cancer segment is further segmented into diffuse bone cancer, nodular bone cancer, and necrotizing bone cancer.
The global market, by diagnostic test & treatment, has been divided into diagnostic test and treatment. The diagnostic test segment is further divided into ultrasonography, complete blood count, biopsy, and others. The treatment segment is bifurcated into medication and surgery. The medication segment is sub-segmented into corticosteroid, nonsteroidal anti-inflammatory drugs, and immunosuppressive-drugs-market-8228'>immunosuppressive drugs. The corticosteroid segment is sub-segmented into difluprednate, prednisolone, and others. The nonsteroidal anti-inflammatory drugs segment is further segmented into aspirin, ibuprofen, and others. The immunosuppressive drugs segment is sub-segmented into methotrexate, mycophenolate, and others.
The end-user segment has been segmented into hospitals & clinics, diagnostic centers, and academic & research organizations.
Bone Cancer Market Key Players
Amgen, Amneal Pharmaceuticals LLC, Baxter International Inc., Boehringer Ingelheim, Fresenius Kabi USA, LLC, Jubilant Cadista Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Novartis Pharmaceuticals, Perrigo Company, Roxane Laboratories, Inc., Sandoz Inc., Shanghai Henlius Biotech, Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals, Zydus Pharmaceuticals (USA) Inc. are some of the key players operating in the global bone cancer market.
Regional Market Summary
Global Bone Cancer Market Share (%), by Region, 2018
Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports
Geographically, the Americas is projected to lead the global market for bone cancer. This can be attributed due to the presence of well-developed healthcare infrastructure and the increasing prevalence of bone cancer within the Americas.
Europe is expected to hold the second-largest share of the bone cancer market owing to government support and presence of developed economies such as the UK, Germany, and France within the region.
The bone cancer market in Asia-Pacific is segmented into China, Japan, India, Australia, South Korea, and the rest of the Asia-Pacific. The region is estimated to grow with the highest CAGR. High prevalence of bone cancer, growing geriatric population, and rising penetration of market players boost the regional market. In India, the mean age of bone cancer patients is estimated to be about 55. This susceptible age group is expanding and growing the treatment-seeking patient pool.
The Middle East & Africa is anticipated to hold the least share of the market owing to the presence of poor economies, stringent government regulations, and low per capita income in Africa. Within the region, the Middle East is projected to lead the market owing to developed healthcare infrastructure and the presence of economies such as Saudi Arabia, Kuwait, and Dubai.
Global Bone Cancer Market, by Type
Global Bone Cancer Market, by Diagnostic Test & Treatment
Global Bone Cancer Market, by End User
Global Bone Cancer Market, by Region
|Market Size||2025: Significant Value|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Diagnostic Test & Treatment, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Amgen, Amneal Pharmaceuticals LLC, Baxter International Inc., Boehringer Ingelheim, Fresenius Kabi USA, LLC, Jubilant Cadista Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Novartis Pharmaceuticals, Perrigo Company, Roxane Laboratories, Inc., Sandoz Inc., Shanghai Henlius Biotech, Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals, Zydus Pharmaceuticals (USA)|
|Key Market Opportunities||
|Key Market Drivers||Increasing healthcare expenditure|
Frequently Asked Questions (FAQ) :
The outlook of the global bone cancer market looks quite assuring.
Fibromyalgia Treatment Market is estimated to expand at 5.6% CAGR throughout the assessment period (2018-2025).
Favorable reimbursement policies, increasing healthcare expenditure, rising R&D investments by the market key players, and growing awareness are the major tailwinds pushing the growth of the global bone cancer market.
North America holds the largest share in the global bone cancer market, followed by Europe and the Asia Pacific, respectively.
Amgen, Baxter International Inc., Amneal Pharmaceuticals LLC, Boehringer Ingelheim, Fresenius Kabi USA, LLC, Mylan Pharmaceuticals Inc., Jubilant Cadista Pharmaceuticals Inc., Novartis Pharmaceuticals, Roxane Laboratories, Inc., Perrigo Company, Sandoz Inc., Teva Pharmaceuticals USA, Inc., Shanghai Henlius Biotech, Zydus Pharmaceuticals (USA) Inc., and West-Ward Pharmaceuticals, are some of the major players operating in the bone cancer market.